Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Annual account missing NBB
Fiscal year 2025 was expected before 31 October 2025 and has not been filed.
Financials
Financial year 2024
D-PHARMA from Schaarbeek, company number BE0455755092, closed financial year 2024 with a result of € 34,289 after tax. For that financial year D-PHARMA recorded a gross margin of € 48,190 and equity of € 284,914. Compared with financial year 2023, the result moved from € 39,937 to € 34,289. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on November 28, 2024.
€ 284,914
▲ 3% vs 2023
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 34,289
▼ 14% vs 2023
Profit after tax over the fiscal year.
€ 35,515
▲ 154% vs 2023
Cash and bank balances on the last day of the fiscal year.
€ 25,000 paid out
73 % of the profit went to the shareholders, mostly to JEOZIF PHARMA (100 % of the shares). That is where the money ends up.
People and assets in 2024
€ 1,549
▼ 42% vs 2023
Book value of vehicles, furniture and equipment.
Debts at end 2024
None
No bank loans on the last day of the fiscal year.
€ 80,063
▲ 61% vs 2023
Supplier invoices still open on the last day of the fiscal year.
€ 7,742
▲ 1% vs 2023
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | Change 2023 → 2024 | |
|---|---|---|---|---|
| Gross margin | € 51,339 | € 49,321 | € 48,190 | ▼ 2% |
| Profit after taxes | € 42,826 | € 39,937 | € 34,289 | ▼ 14% |
| Equity | € 260,687 | € 275,625 | € 284,914 | ▲ 3% |
| Total debts | € 90,488 | € 87,344 | € 117,975 | ▲ 35% |
| Cash | € 17,737 | € 13,972 | € 35,515 | ▲ 154% |
| Retained profit | € 242,095 | € 257,033 | € 266,322 | ▲ 4% |
| Dividend | € 25,000 | € 25,000 | € 25,000 | |
| Balance sheet total | € 376,175 | € 387,969 | € 427,889 | ▲ 10% |
Key figures of D-PHARMA, fiscal years 2022 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 October 2025.
What happened to D-PHARMA?
What happened at D-PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2024: profit of € 34,289 (▼ 14% vs 2023). filed late Source: NBB ↗
- New establishment in Schaarbeek. KBO
- Start of the company according to the CBE. KBO
In short
From € 42,826 profit in 2022 to € 34,289 profit in 2024.
Paid € 18,824 in corporate taxes since 2022.
Best year ever: 2022, with € 42,826 profit.
Paid out € 75,000 in dividends to the owners in total.
A new publication or filing at D-PHARMA? We notify you, reason included.
Follow D-PHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of JEOZIF PHARMA comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
D-PHARMABehind D-PHARMA is Jeozif Pharma. The shares are held by JEOZIF PHARMA (100%).
Directors
According to the 2024 annual accounts
Manager · represented by Jeozif Butros
Shareholders
100%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Jan Stobbaertslaan 10
1030 Schaarbeek
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0455.755.092
- VAT number
- BE 0455.755.092
- Registered office
- Jan Stobbaertslaan 10, 1030 Schaarbeek
- Names & denominations
- D-PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 11 July 1995
- Peppol
- Active · Active since 31 Dec 2025
- Activities · NACE
Detailhandel in farmaceutische producten
Apothekers